Seattle biotechnology company Oncothyreon has acquired another local firm, Alpine Biosciences, for about $27 million in stock.
Alpine Biosciences, an early stage company that has not advanced any drugs into clinical trials, was formed by Mitch Gold, who stepped down as CEO of Dendreon in 2012, and Jay Venkatesan, a doctor and biotech investment manager. The company has licensed nanoparticle technology it says can “encapsulate” large drug molecules and deliver them to targeted cells for treating diseases.
The 9.3 million shares paid for Alpine represent about one eighth of the company’s currently outstanding stock. Oncothyreon, which has a market capitalization of about $216 million, said Venkatesan will join the company as an executive vice president.
Oncothyreon has several cancer drugs in clinical trials, and collaboration deals with larger biotech and pharmaceutical companies.
Most Read Business Stories
- Report spotlights how some owners of high-end Seattle condos conceal their identities
- Seattle's first Opportunity Zone development breaks ground in Pioneer Square; hopes to buck ‘tax scam’ label
- Questions raised about photos used as evidence of repairs in Lion Air, Boeing 737 MAX crash investigation
- Qantas, Boeing Dreamliner to embark on world's first 20-hour airline flight
- Longtime Seattle property group Unico buys Westlake Tower for $236 million